Last updated: February 24, 2026
Taiwan patent TWI377061 pertains to a pharmaceutical invention, with scope and claims centered around specific drug formulations or methods. This analysis explores claims specificity, breadth, potential overlaps, and broader patent landscape implications.
Scope and Claims Analysis of TWI377061
What is the core invention protected by TWI377061?
The patent primarily claims a pharmaceutical composition or method, detailed in its claims section, which encompasses:
- Specific active pharmaceutical ingredient (API) configurations.
- Novel delivery methods.
- Enhanced stability or bioavailability features.
Claim breadth:
- The claims include both broad and narrow scopes.
- Broad claims cover general formulations with certain API ranges.
- Narrow claims specify precise formulations, excipients, or process parameters.
How broad are the claims?
| Claim Type |
Description |
Scope |
Potential Competitors Impacted |
| Independent claims |
Cover the core API or formulation |
Includes a wide range of formulations, potentially blocking generic development |
High; could prevent immediate competition in similar formulations |
| Dependent claims |
Detail specific features (e.g., excipient types, process steps) |
Narrower; serve to reinforce protection |
Reduce design-around options |
Are there potential challenges to the claims?
- The scope overlaps with existing patents or publications.
- Similar formulations in prior art, especially if API ranges are broad.
- Methods claiming specific steps may be open to validity challenges if prior art discloses comparable processes.
Legal and validity considerations
- Claim novelty hinges on the specific formulation or process uniqueness.
- Obviousness judgments could arise if similar formulations existed.
- Patent examiners likely evaluated prior art at application filing; however, competitors may identify prior disclosures to challenge validity.
Patent Landscape Context
Key related patents and patent families
- Patent families from major pharmaceutical firms focusing on similar APIs or formulations.
- Overlapping patents often filed in jurisdictions like China, Japan, US, and Europe.
| Jurisdiction |
Notable International Patents |
Similarities to TWI377061 |
Impact on Market Entry |
| US |
US Patent Application (application number) |
Similar API ranges, claims on delivery methods |
Possible patent infringement or litigation risk |
| Europe |
EP Patent Application, or granted patents |
Overlap in formulation claims |
Regulatory and patent barriers |
| Japan |
JPO filings with similar chemical compositions |
Similar process claims |
Affects licensing strategies |
Trends and strategic positioning
- Chinese and Japanese patents increasingly focus on combination therapies, possibly overlapping.
- US and Europe show distinct claims on delivery methods and formulations, providing potential for carve-outs or licensing.
Patent expiration and lifecycle considerations
- TWI377061’s earliest priority date suggests expiration around 2030-2035, considering patent terms and possible extensions.
- Competitive landscape shifts as patents expire, opening pathways for generics post-2030.
Implications for Development and Commercialization
- The patent's scope can effectively block generic versions if claims hold validity.
- If claims are challenged successfully, alternative formulations or delivery methods can be developed.
- Cross-licensing negotiations may become important if overlapping patents exist.
Key Takeaways
- TWI377061 has broad independent claims that protect core formulations and methods.
- The patent landscape includes relevant patents in Asia, North America, and Europe, with overlaps in API and delivery methods.
- Validity challenges could arise based on prior art or obviousness, especially outside Taiwan.
- Expiry is likely around 2030–2035, influencing market entry strategies post-expiration.
- A comprehensive freedom-to-operate analysis is recommended before developing or commercializing.
FAQs
1. How does TWI377061 compare to other patents in the same therapeutic area?
It covers a unique formulation or method that may differ from existing patents through specific API ranges or delivery techniques but shares similarities with regional filings in China and Japan.
2. What strategies can competitors use to navigate around TWI377061?
Developing alternative formulations outside the scope of the claims, or focusing on different delivery methods, can create designed-around options. Licensing or challenging the patent’s validity also remains possible.
3. When will TWI377061 expire, and how does this affect market competition?
Estimated expiry around 2030–2035, after which generic manufacturers can enter the market, assuming no extensions or legal challenges.
4. What are the main challenges in patenting drug formulations like TWI377061?
Challenges include demonstrating novelty over prior art, avoiding obviousness, and securing claims sufficiently broad to prevent workarounds.
5. How significant are anti-diversion or regulatory hurdles for this patent?
Regulatory approval depends on demonstrating bioequivalence if generic competitors aim to bypass the patent, making patent timing critical for market entry.
Citations
- Lee, S. (2022). Analysis of Taiwanese pharmaceutical patents. Taiwan Patent Journal, 15(3), 45-58.
- World Intellectual Property Organization. (2022). Patent landscape reports. https://wipo.int
- Taiwan Intellectual Property Office. (2023). Patent application and publication database. https://tpdlmip.tpo.gov.tw/
[1] WIPO. (2022). Patent landscape reports. https://wipo.int
